RxDoctor Payments Data

Grace Wong, MD

Internal Medicine · Burbank, CANPI 1053504902

Payments from drug & device makers

$2,307in general payments, 2019–2025

Across 116 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$383
  • Amgen$255
  • Novo Nordisk$218
  • GSK$160
  • Phathom Pharmaceuticals, Inc.$156
  • Shield Therapeutics Inc$148
  • plus $987 from 21 others

What the payments were for

  • Food & beverage$2,307100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,307 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$171,898
Medicare patients
544
Services billed
2,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$75,676
EliquisApixaban81$51,801
JanuviaSitagliptin Phosphate45$39,211
JardianceEmpagliflozin47$31,331
RybelsusSemaglutide25$24,943
XareltoRivaroxaban29$19,218
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$12,919
Sildenafil Citrate16$4,273
JanumetSitagliptin Phos/Metformin Hcl12$4,263
Sucralfate24$3,353
Albuterol Sulfate HfaAlbuterol Sulfate84$2,520
Humalog Kwikpen U-100Insulin Lispro14$2,341
SynthroidLevothyroxine Sodium27$2,280
Rasagiline Mesylate14$2,173
Atorvastatin Calcium293$2,115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$218$100,619100 claims
PfizerEliquis$56$51,80181 claims
MerckJanuvia, Janumet$20$43,47457 claims
Boehringer IngelheimJardiance$111$31,33147 claims
Johnson & JohnsonXarelto$41$19,21829 claims
GSKTrelegy Ellipta$160$12,91918 claims
AbbVieSynthroid$383$2,28027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Burbank

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →